Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Mogamulizumab-associated rash in CTCL

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, discusses one of the main side effects induced by mogamulizumab therapy in patients with cutaneous T-cell lymphoma (CTCL), mogamulizumab-associated rash (MAR). These rashes occur due to reprogramming of the immune system and are clinically and histologically heterogenous. Dr Bagot reports that MAR appears to be associated with better response to treatment and improved prognosis. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.